Novo Nordisk's Alhemo drug has been recommended for European approval as a treatment for hemophilia, the company said Friday.

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

We recently published an article titled, Jim Cramer’s Latest Lightning Round: 12 Stocks to Watch. In this article, we are ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...

Novo Nordisk NVO has outperformed the market over the past 10 years by 6.26% on an annualized basis producing an average ...

Eighty states, cities, counties, school boards and unions have joined litigation in a New Jersey district court against the three major pharmacy middlemen.

Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena ...

Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to ...

Semaglutide, the same compound that’s in Ozempic, is part of a class of medications known as glucagon-like peptide 1 (GLP-1) ...

A CNBC investigation into illegal weight loss drugs reveals a marketplace where criminals brazenly counterfeit the drugs or ...